NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: FREDUN · data 2026-10-31
Fredun Pharmaceuticals Ltd.
In plain words
Price: 17.9% below its 52-week high of ₹1,665.
Delivery: 49.7% of traded shares were kept for delivery over the last 10 sessions, against 49.7% over the last 52.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹748 cr |
| Net profit (last 12 months) | ₹44 cr |
| Sales growth, 3 years (yearly) | 32.5% |
| Profit growth, 3 years (yearly) | 44.5% |
At a glance
P/E 49.7, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 15.6%, ROCE 33.0%, operating margin 13.4%: how much profit it earns on the money it uses.
Debt/equity 0.87, Profit growth 44.5% and sales growth 32.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 44.5% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
14/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 9/30: Delivery 31.6% over the last 20 sessions vs 49.1% in the 40 before (0.64x); shares delivered per day 1.94x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Fredun Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.87.
What is Fredun Pharmaceuticals Ltd.'s P/E ratio?
About 49.7, based on the last 12 months' earnings and a price of ₹1,367 (data 2026-10-31).
What is the 52-week high and low of Fredun Pharmaceuticals Ltd.?
The 52-week high is ₹1,665 and the 52-week low is ₹1,195.2.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Fredun Pharmaceuticals Ltd. | ₹1,367 | ₹2,259 cr | 49.7 | — | 15.6% | 33% | 0.87 | -11.2% |
| Sai Parenterals Limited | ₹521.95 | ₹2,302 cr | — | — | 4.9% | 5.8% | 0.96 | +30.5% |
| Dishman Carbogen Amcis Ltd. | ₹145.02 | ₹2,276 cr | 33.3 | — | 1.6% | 2.6% | 0.46 | -50.5% |
| Alembic Limited | ₹87.22 | ₹2,239 cr | 7 | — | 13.3% | 3.3% | 0 | -13.2% |
| Sakar Healthcare Ltd | ₹944.8 | ₹2,074 cr | 49 | 6.1 | 10% | 12.4% | 0.17 | +167.0% |
| Beta Drugs Ltd. | ₹1,798.4 | ₹2,000 cr | 36.9 | 4.6 | 18.8% | 16.6% | 0.62 | -4.8% |
Compare FREDUN with SAIPARENT in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open FREDUN in NSE Scanner →